A Study in the Management of Anxiety with Lorazepam

Abstract

A 4 wk double-blind comparison between lorazepam and placebo involving 60 patients with anxiety revealed that lorazepam in a mean dose of approximately 3 mg on a b.i.d. [twice a day] regimen is significantly and clinicaly more effective than placebo for almost all items of the Global, Hamilton and 35-Item scales at nearly all evaluation periods. Lorazepam was associated with a 50% greater improvement rate than was placebo. Except for only 1 patient who was withdrawn from the study because of severe sedation, lorazepam was well tolerated and did not interact adversely with concomitant nonpsychoactive medication.